SHC1: A Protein Targeted for Drug Development (G6464)

Target Name: SHC1

NCBI ID: G6464

SHC1

SHC1: A Protein Targeted for Drug Development

SHC1 (SHC-transforming protein 1) is a protein that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an intriguing target for researchers to study, and its potential as a drug or biomarker has led to a great deal of interest in the field of biotechnology.

SHC1 is a transmembrane protein that is expressed in many different tissues and cells in the body. Its primary function is to act as a chaperone, helping to transport and present proteins to their proper destinations on the cell surface. This protein is also involved in cell signaling, as it has been shown to play a role in the regulation of cell proliferation and differentiation.

One of the key features of SHC1 is its ability to transform other proteins into new forms. This process, known as protein degradation, is important for the regulation of many different proteins, including those involved in diseases such as cancer and neurodegenerative diseases. By allowing the degradation of certain proteins, SHC1 has been shown to play a negative role in the development and progression of these diseases.

Another important function of SHC1 is its role in the regulation of cell signaling. SHC1 has been shown to play a negative role in the regulation of cell proliferation and differentiation, as well as in the regulation of cell survival. This suggests that it may be a potential drug target for diseases that involve these processes, such as cancer and neurodegenerative diseases.

In addition to its role in cell signaling, SHC1 has also been shown to play a role in the regulation of the immune system. This protein has been shown to play a key role in the development and regulation of T cells, which are a crucial part of the immune system.

The potential implications of SHC1 as a drug target or biomarker are significant. If SHC1 is indeed effective in preventing or treating the development and progression of diseases, it could be a valuable tool for the development of new treatments. Additionally, SHC1's ability to transform other proteins into new forms could be a valuable tool for the development of new drugs or biomarkers.

Overall, SHC1 is a protein that has the potential to be a valuable drug target or biomarker for a variety of diseases. Further research is needed to fully understand its function and potential as a drug.

Protein Name: SHC Adaptor Protein 1

Functions: Signaling adapter that couples activated growth factor receptors to signaling pathways. Participates in a signaling cascade initiated by activated KIT and KITLG/SCF. Isoform p46Shc and isoform p52Shc, once phosphorylated, couple activated receptor tyrosine kinases to Ras via the recruitment of the GRB2/SOS complex and are implicated in the cytoplasmic propagation of mitogenic signals. Isoform p46Shc and isoform p52Shc may thus function as initiators of the Ras signaling cascade in various non-neuronal systems. Isoform p66Shc does not mediate Ras activation, but is involved in signal transduction pathways that regulate the cellular response to oxidative stress and life span. Isoform p66Shc acts as a downstream target of the tumor suppressor p53 and is indispensable for the ability of stress-activated p53 to induce elevation of intracellular oxidants, cytochrome c release and apoptosis. The expression of isoform p66Shc has been correlated with life span (By similarity). Participates in signaling downstream of the angiopoietin receptor TEK/TIE2, and plays a role in the regulation of endothelial cell migration and sprouting angiogenesis

The "SHC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SHC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets